Wednesday, 9 July 2025
30.9 C
Singapore
33 C
Thailand
25.4 C
Indonesia
29.2 C
Philippines

23andMe to lay off 40% of workforce amid cost-cutting drive

23andMe cuts 40% of its workforce, saving US$35M, to refocus on core services after a tough year with layoffs and a data breach.

In a significant restructuring move, genetic testing company 23andMe announced on Monday that it is reducing its workforce by 40%, affecting over 200 employees. This decision is part of a broader strategy to cut costs as the company re-focuses on its core genetic testing services and strategic research partnerships.

CEO outlines cost-cutting measures and strategic changes

23andMe’s CEO and co-founder Anne Wojcicki described the layoffs as a “difficult but necessary” step to secure the company’s long-term stability. The layoffs are expected to save 23andMe more than US$35 million, enabling it to streamline its operations while concentrating on its primary consumer products and research collaborations.

In a statement, Wojcicki expressed sympathy for the affected employees but noted the urgency of reducing costs. “These actions were not easy, but they are critical for our continued focus on what we do best: providing trusted genetic information to consumers and building valuable partnerships that advance research.”

Therapeutics programs set to close as company shifts focus

Alongside the layoffs, 23andMe confirmed plans to discontinue its therapeutics division, which has focused on drug development using data from its vast genetic database. The company’s therapeutics programs, which included two immuno-oncology initiatives, aimed to develop new cancer treatments by harnessing the body’s immune system to target cancer cells. According to the therapeutics division’s website, these programs were designed to “restore the ability of the body’s immune cells to kill cancer cells.”

Despite years of investment, 23andMe’s therapeutic ventures have faced challenges. While the company’s genetic data has been valuable in providing insights for personalised healthcare and genetic research, the shift away from drug development marks a strategic pivot. Shutting down these programs will allow 23andMe to dedicate its resources and expertise to the core areas of consumer genetic testing and research partnerships.

Challenges and setbacks in the past year

The restructuring follows a challenging year for 23andMe, which has faced both security and financial setbacks. In April of last year, the company became the target of a significant cybersecurity breach, which exposed the personal data of 6.9 million users. The breach reportedly went undetected for over 18 months, raising serious concerns about the company’s data protection practices.

Following the breach, 23andMe was subject to a US$30 million settlement in a class-action lawsuit, and the scandal led to the resignation of the entire board of directors. These events have pressured the company to improve its data security and rebuild its reputation with consumers, investors, and regulatory bodies.

This series of challenges has pushed 23andMe to re-evaluate its business model. By focusing on genetic testing and its associated research partnerships, 23andMe hopes to stabilise financially and continue offering its unique services to millions of customers. However, these significant layoffs and program closures indicate that the company’s journey to recovery may still face obstacles.

23andMe was founded in 2006, gaining a reputation for its affordable, at-home genetic testing kits that provide insights into ancestry and health predispositions. Over the years, it has expanded into medical research, working with pharmaceutical companies to leverage its extensive genetic database. Despite its successes in these areas, the company now seems intent on narrowing its focus to core services while reducing the scale of its operations.

The company has not yet detailed specific support measures for employees affected by the layoffs, though it has expressed commitment to assisting them during the transition. As the company scales back on its drug development ambitions, 23andMe’s primary focus will remain on consumer genetic insights and research-driven partnerships.

Hot this week

Okta warns of AI-powered phishing infrastructure built with v0.dev

Okta reports that attackers are using AI tool v0.dev to rapidly create phishing infrastructure, urging organisations to adopt passwordless security.

Windows 11 has finally become the most popular desktop operating system

Windows 11 overtakes Windows 10 in desktop market share as Microsoft prepares to end support for its older system in October.

Stop Killing Games hits 1.2 million signatures, but challenges remain

The Stop Killing Games petition passed 1.2M signatures, but fake entries and industry pushback may slow its path to EU law.

Microsoft opens pre-orders for Surface Copilot+ PCs in Singapore

Microsoft launches AI-powered Surface Pro and Surface Laptop in Singapore, with pre-orders open ahead of 15 July availability.

Google to roll out update for Pixel 6A battery overheating next week

Google’s July 8 Pixel 6A update limits battery overheating by reducing capacity after 400 cycles, with free replacements for affected users.

GenAI transforms online shopping experience as Prime Day sales soar

AI takes the spotlight this Prime Day as GenAI tools reshape how people shop, find deals, and make purchase decisions online.

Apple COO Jeff Williams to retire, Sabih Khan named successor

Apple COO Jeff Williams to retire later this year; Sabih Khan to take over as the company prepares for a smooth executive transition.

Best action cameras in 2025 for every adventure: From budget picks to pro-grade gear

Discover the best action cameras in 2025 for every adventure, from budget-friendly options to pro-level gear with 8K video, advanced stabilisation, and rugged designs.

Microsoft’s Copilot Plus features may come to desktops by late 2025

Intel’s Arrow Lake Refresh may bring Copilot Plus AI tools to desktop PCs by late 2025, with a focus on enhanced NPU support.

Related Articles

Popular Categories